Antibodies
29 October 2014
Xencor Renegotiates XmAb®5871 Agreement with Amgen; Regains All Rights and Plans Clinical Development in Rare Autoimmune Disease28 October 2014
Innate Pharma presents two posters on proprietary BTG-ADC technology at the world ADC Summit27 October 2014
Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer24 October 2014
Further preclinical studies emphasise the potential of Indatuximab Ravtansine (BT-062) in solid tumours23 October 2014
ABLYNX’S ANTI-IL-6R NANOBODY PARTNERED WITH ABBVIE DEMONSTRATES A BIOAVAILABILITY OF MORE THAN 80% AFTER SUBCUTANEOUS INJECTION21 October 2014
MabVax Therapeutics Nominates The Fully Human Antibody HuMab 5B1 As The Company’s Lead Clinical Development Candidate20 October 2014
Sanofi : Sanofi and Regeneron Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis17 October 2014
AbGenomics Announces IND Filing for AbGn-168H (Neihulizumab) to Treat Psoriatic Arthritis12 October 2014
Janssen Submits Application Seeking Approval Of STELARA® In European Union For Pediatric Plaque Psoriasis10 October 2014
Novartis data at EADV show consistent efficacy of AIN457 (secukinumab) in clearing skin of psoriasis patients10 October 2014
Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia10 October 2014
Sobi’s collaboration partner Biogen Idec files marketing authorisation application for Elocta(TM) (rFVIIIFc) in Europe9 October 2014
XOMA Launches XOMA 358 Clinical DevelopmentNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports